PINK1 and Parkinson disease: In summary, our preclinical data show that intranasal administration of CNS/CT-001 can reverse motor symptoms of PD, the loss of hind limb strength, reduce the number of total levels of α-synuclein aggregates in the cortex and significantly reverse neurodegeneration of midbrain dopamine neurons in symptomatic PINK1-KO rats.